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OBJECTIVE—The endocannabinoid (EC) system has been
implicated as an important regulator of energy homeostasis. In
obesity and type 2 diabetes, EC tone is elevated in peripheral
tissues including liver, muscle, fat, and also centrally, particularly
in the hypothalamus. Cannabinoid receptor type 1 (CB1) block-
ade with the centrally and peripherally acting rimonabant in-
duces weight loss and improves glucose homeostasis while also
causing psychiatric adverse effects. The relative contributions of
peripheral versus central EC signaling on glucose homeostasis
remain to be elucidated. The aim of this study was to test whether
the central EC system regulates systemic glucose ﬂuxes.
RESEARCH DESIGN AND METHODS—We determined glu-
cose and lipid ﬂuxes in male Sprague-Dawley rats during in-
tracerebroventricular infusions of either WIN55,212-2 (WIN) or
arachidonoyl-2’-chloroethylamide (ACEA) while controlling cir-
culating insulin and glucose levels through hyperinsulinemic,
euglycemic clamp studies. Conversely, we fed rats a high-fat diet
for 3 days and then blocked central EC signaling with an intra-
cerebroventricular infusion of rimonabant while assessing glu-
cose ﬂuxes during a clamp.
RESULTS—Central CB1 activation is sufﬁcient to impair glucose
homeostasis. Either WIN or ACEA infusions acutely impaired in-
sulin action in both liver and adipose tissue. Conversely, in a
model of overfeeding-induced insulin resistance, CB1 antagonism
restored hepatic insulin sensitivity.
CONCLUSIONS—Thus central EC tone plays an important role
in regulating hepatic and adipose tissue insulin action. These re-
sults indicate that peripherally restricted CB1 antagonists, which
may lack psychiatric side effects, are also likely to be less effec-
tive than brain-permeable CB1 antagonists in ameliorating insulin
resistance. Diabetes 60:1055–1062, 2011
O
besity and type 2 diabetes continue to be
growing health concerns of pandemic pro-
portions in developed and developing nations.
Insulin resistance is a hallmark of both of these
conditions and leads to impaired glucose and lipid homeo-
stasis. This often leads to multiple complications, includ-
ing fatty liver, atherosclerosis, and cardiovascular disease,
which reduce life expectancy (1). Insulin is the principal
regulator of both glucose and lipid homeostasis. It lowers
circulating glucose levels by decreasing hepatic glucose
production (hGP) and increasing glucose uptake into
peripheral tissues like muscle and fat (2). Insulin suppresses
hGP through direct effects via hepatic insulin receptors and
indirect mechanisms, including the activation of neuronal
insulin signaling (3,4) and the modulation of gluconeogenic
substrate ﬂux from adipose tissue by suppressing lipolysis
(5,6). Hepatic insulin resistance is deﬁned as the inability of
systemic hyperinsulinemia to suppress hGP and contributes
to both fasting and postprandial hyperglycemia seen in
patients with obesity and type 2 diabetes (7). With regards to
adipose tissue, insulin resistance is deﬁned as the inability of
hyperinsulinemia to suppress lipolysis (8). Unrestrained li-
polysis is an important contributor to the pathogenesis of
type 2 diabetes since elevated free fatty acids induce lipo-
toxicity and further worsen insulin resistance (9).
We have recently shown that hypothalamic insulin sig-
naling is an important determinant of adipose tissue insulin
action (10) and have conﬁrmed the ﬁndings of others that
it also regulates hGP (3). Insulin binds to receptors on hy-
pothalamic neurons that eventually activate ATP-sensitive
potassium channels, leading to the hyperpolarization of
neurons (11). Through synaptic transmission, the resulting
signal is then conveyed to second-order neurons (12),
which regulate hepatic metabolism through what appear to
be predominantly vagal efferents (11). Furthermore, we
have found that insulin infused either into the third ventricle
or, more speciﬁcally, into the mediobasal hypothalamus
(MBH), restrains white adipose tissue (WAT) lipolysis by
dampening sympathetic outﬂow to WAT. Moreover, insulin
resistance caused by one day overfeeding is in part due to
impaired hypothalamic insulin action (10,13), which is a
failure of intracerebroventricular or MBH infused insulin to
suppress hGP and adipose tissue lipolysis. However, the
mechanism underlying this decreased hypothalamic insulin
action remains unclear. Some publications suggest that
decreased insulin signaling in the hypothalamus accounts
for this impaired insulin action (13). On the other hand, it is
possible that the insulin signaling cascade in the hypothal-
amus is intact but the synaptic transmission of this neuronal
signal from the hypothalamus to the liver and WAT might
be impaired.
The endocannabinoid (EC) system plays an important
role in the regulation of energy homeostasis (14), speciﬁ-
cally of glucose and lipid homeostasis, and represents an
important link between obesity and insulin resistance. The
EC system is composed of the cannabinoid receptors (CB1
[15,16] and CB2 [15]), their endogenous ligands (the ECs),
such as anandamide and 2-arachidonylglycerol, and the
enzymes responsible for the synthesis and degradation of
the ECs (17). CB1 is present throughout the brain (16,17)
and also in many peripheral tissues, including liver, mus-
cle, and WAT (15). Several studies have demonstrated that
in obese or diabetic rodents and humans, EC tone is ele-
vated in adipose tissue, liver, and pancreas (18,19) but also
in the brain, particularly the hypothalamus (20,21).
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ORIGINAL ARTICLESystemic CB1 activation increases food intake, de-
creases energy expenditure, and disrupts glucose and lipid
homeostasis by inducing insulin resistance (14,21,22).
Furthermore, selective CB1 blockade, through pharmaco-
logical means (23,24) or genetic knockout of CB1 (25),
decreases food intake and body weight and markedly
improves insulin sensitivity, glucose, and lipid homeostasis
in obesity (26). The relative contributions of peripheral
versus central EC signaling to impairing glucose and lipid
homeostasis are yet to be determined. ECs are thought to
regulate appetite through central, hypothalamic effects
(27), and peripheral metabolism through direct effects on
target organs (28), such as the liver and WAT. The question
of where excessive CB1 signaling dysregulates glucose and
lipid ﬂuxes has clinical relevance. Although systemic CB1
blockade in humans, through medications like rimonabant
and taranabant (29), improves glucose and lipid homeo-
stasis, it also signiﬁcantly increases the risk of psychiatric
adverse events, including depression and suicidal ideation
(30). This led to the retraction of these otherwise suc-
cessful antiobesity medications (31).
Prior studies have attempted to separate the brain effects
of ECs from their systemic effects (32,33,34). These studies
were inconclusive because they lacked a truly peripherally
restricted CB1 antagonist (32). A recent study demonstrated
improvements greater than pair-fed vehicle but still less
than rimonabant through peripheral CB1 blockade (33).
Another study found that rimonabant was ineffective in
mice lacking CB1 in neurons, highlighting the impact of
neuronal CB1 (34), but did not answer the question of
whether this was through CB1 in the central nervous sys-
tem (CNS) or in peripheral sympathetic ganglions.
The aim of our study was to explore the role of central
EC system activation on hepatic insulin sensitivity in vivo.
Because ECs can act as retrograde, inhibitory messengers
in the brain (17,35), we hypothesized that elevated brain
EC signaling would inhibit the propagation of insulin-
induced neuronal signals, resulting in decreased insulin
action potentially in the absence of any hypothalamic in-
sulin signaling defect. Therefore, the activation of CB1 in the
brain should dampen the ability of insulin to suppress hGP.
Conversely, overfeeding-induced insulin resistance should
be ameliorated by CB1 blockade in the brain. Our results
support this hypothesis, demonstrating that the activation
of CB1 in the brain impairs hepatic insulin sensitivity,
whereas central CB1 antagonism restores insulin sensitiv-
ity. Interestingly, we ﬁnd that central CB1 activation also
impairs the ability of systemic insulin to suppress lipolysis.
RESEARCH DESIGN AND METHODS
Animals. Animal protocols were approved by the Mount Sinai School of
Medicine Institutional Animal Care and Use Committee. Male Sprague-Dawley
(SD) rats (8 weeks old) (Charles River Breeding Laboratories, Wilmington, MA)
were fed a standard rodent diet (Rodent Diet 5001; LabDiet, St. Louis, MO)
and housed in a temperature- and light-controlled (21°C, 12-h light-dark
cycle) facility. Rats were stereotaxically ﬁtted with 22-gauge intracerebro-
ventricular guide cannulae (PlasticsOne, Roanoke, VA) targeting the third
ventricle, 2.5 mm posterior from bregma, on the midline 9 mm below the
cortical surface, 2 weeks before the clamp study. One week later carotid ar-
terial and jugular venous catheters were implanted for blood sampling and
infusion, respectively. Rats recovered for at least 4 days and returned to within
10% of their presurgical body weight before being studied. After recovering
from surgery, rats participating in the rimonabant study were given highly
palatable 10% lard diet (HFD) (Modiﬁed Laboratory w/ 10% Lard 57IR, Lab-
Diet) for 3 days before the clamp while food intake was monitored.
Pancreatic hyperinsulinemic-euglycemic clamp studies. The rat clamp
studies have been described previously (10) and are depicted schematically in
Fig. 1A. In brief, intracerebroventricular infusion cannulae were inserted and
a5mL/h intracerebroventricular infusion was initiated (t = 2120 min) and
maintained throughout the study. Treatments dissolved in artiﬁcial cerebro-
spinal ﬂuid (aCSF) (Harvard Apparatus, Holliston, MA) contained 0.25 mg/mL
WIN55,212-2 (WIN) (Sigma-Aldrich, St. Louis, MO; soluble with 5% DMSO, 0.5%
Tween-80), 36.5 ng/h arachidonoyl-2’-chloroethylamide (ACEA) (with 0.036%
DMSO), 0.2 mg/mL rimonabant (with 0.35% DMSO, 0.02% Tween-80) (both
Cayman Chemical, Ann Arbor, MI), or the appropriate vehicle composed of
aCSF, DMSO, and Tween 80 as needed for treatment solubility.
At t = 0 min, we started a tracer equilibration period consisting of primed-
continuous infusions of [
3H-3]glucose (radiochemical concentration .97%;
PerkinElmer, Waltham, MA) and [
2H-5]glycerol (98 atom percent excess from
Isotec [Miamisburg, OH]) with boluses of 20 mCi and 13.3 mmol followed by
continuous infusions of 0.5 mCi/min and 0.334 mmol/min, respectively. At t =
90 min, blood samples were taken every 10 min to determine basal hGP and
Ra glycerol. At t = 120 min, an insulin clamp began with primed-continuous
infusions of human insulin (Humulin R, Lilly; Indianapolis, IN) and somatostatin
(Bachem Biosciences; Torrance, CA) with boluses of 53.2 mU $ kg
21 and 53.2
mg $ kg
21 followed by infusions at 3 mU $ kg
21 $ min
21 and 3 mg $ kg
21 $ min
21,
respectively, while continuing the tracer infusions at the aforementioned rates.
Euglycemia was maintained by measuring blood glucose and infusing 25%
glucose as necessary. Blood samples were obtained every 10 min for the last
hour of the experiment to calculate hGP, Rd of glucose, and Ra glycerol under
clamped conditions.
Analytic procedures. At the end of the clamp, rats were anesthetized and
killed and tissue samples were freeze-clamped in liquid nitrogen and stored at
280°C. Blood was collected in EDTA tubes. Blood glucose was measured by
the GM9-D glucose analyzer (Analox Instruments, London, U.K.). Plasma in-
sulin was analyzed by a rat insulin ELISA from Mercodia (Uppsala, Sweden).
Plasma nonesteriﬁed fatty acid (NEFA) and trigylcerides were measured by
kits from Wako Diagnostics (Richmond, VA) and Sigma-Aldrich.
Glucose ﬂuxes. Plasma samples were deproteinated using barium hydroxide
and zinc sulfate, centrifuged, and the supernatant was dried overnight to
eliminate tritiated water. Glucose was redissolved in water and counted using
Ultima Gold in a MicroBeta TriLux (both PerkinElmer) liquid scintillation
counter. Under preclamp steady-state conditions, hGP equals the glucose
turnover rate, which was determined from the ratio of the [
3H-3]glucose tracer
infusion rate and the speciﬁc activity of plasma glucose. During the clamp,
hGP was calculated by subtracting the exogenous glucose infusion rate (GIR)
from the glucose turnover rate, which in a steady state equals the Rd.
Glycerol ﬂuxes. Ra glycerol (in mmol $ kg
21 $ min
21) was calculated by the
equation:
Ra ¼

ENRinf
ENRpl
21

:  R
where ENRinf is the fractional isotopic enrichment of the infused glycerol in
atom percent excess and ENRpl is the enrichment in the plasma sample. R is
the rate of isotope infusion in mmol $ kg
21 $ min
21 (36). The
2H-labeling of
plasma glycerol was determined as follows: 20 ml of plasma was deproteinated
with 200 ml methanol by centrifugation. The ﬂuid fraction was dried and
reacted with 50 ml bis(trimethylsilyl)triﬂuoroacetamide plus 10% trimethyl-
chlorosilane for 20 min at 75°C. Isotope enrichment was determined by gas
chromatography–mass spectrometry. Ions of 205–208 mass-to-charge ratios
were monitored.
Western blot analyses. Western blots were performed as in Ref. 10. In brief,
proteins were extracted from tissue, separated on 4–12% NuPAGE gels (In-
vitrogen, Carlsbad, CA), blotted onto Immobilon-FL PVDF (Millipore, Billerica,
MA) membranes, blocked, and incubated with primary antibodies. Antibodies
used were: phospho-Akt473, GSK3-a/b, phospho-hormone–sensitive lipase
(HSL) (Ser563 and Ser660), adipose triglyceride lipase (ATGL), PKA Substrate
(all Cell Signaling Technology, Beverly, MA), b-actin, total HSL, and GAPDH
(all Abcam, Cambridge, MA). Perilipin and CGI-58 were gifts from Drs. Andrew
Greenberg (37) and Dawn Brasaemle (38), respectively. Phosphoperilipin was
assessed by the PKA Substrate motif antibody. Blots were washed, incubated
with Dylight conjugated secondary antibodies (Thermo Fisher Scientiﬁc,
Waltham, MA) against rabbit and mouse IgG, and then washed before being
scanned with the LI-COR Odyssey (LI-COR, Lincoln, NE) and quantiﬁed with
Odyssey 3.0 software on the basis of direct ﬂuorescence measurement.
Statistics. Values are presented as means 6 SE. Comparisons between groups
were made using unpaired, two-tailed Student t tests. Differences were con-
sidered statistically signiﬁcant at P , 0.05.
RESULTS
Central EC system activation induces hepatic insulin
resistance. To assess the effects of central CB1 activation
on systemic insulin action, the authors performed hy-
perinsulinemic (3 mU $ kg
21 $ min
21), euglycemic clamp
BRAIN ENDOCANNABINOIDS REGULATE NUTRIENT FLUXES
1056 DIABETES, VOL. 60, APRIL 2011 diabetes.diabetesjournals.orgstudies in SD rats while infusing the CB1 agonist WIN
(protocol in Fig. 1A). This protocol consisted of a 4-h
baseline period followed by a 2-h hyperinsulinemic clamp.
Glucose levels were controlled, and insulin concentrations
were equal between groups before and during the clamp
(Fig. 1B and Supplementary Fig. 1A). We used tracer di-
lution methodology to assess glucose and lipid ﬂuxes si-
multaneously through the utilization of [
3H-3]glucose and
[
2H-5]glycerol, respectively.
During baseline, the intracerebroventricular infusion of
WIN tended to elevate hGP compared with vehicle, al-
though this did not reach statistical signiﬁcance. During
the clamp, whereas systemic hyperinsulinemia lowered
hGP in the vehicle infused rats, intracerebroventricular
administration of WIN signiﬁcantly blunted this effect
(Fig. 1C). Although vehicle-infused rats suppressed hGP
by 85% during the clamp, rats infused with WIN only
suppressed hGP by 52% (Fig. 1D), indicating impaired
hepatic insulin action. Of note, the rate of glucose utili-
zation (Rd) in peripheral tissues, such as muscle and
fat, tended to be higher in the WIN-infused animals
(Fig. 1E), which could account for the fact that we did not
ﬁnd differences in the GIR (Supplementary Fig. 1B).
These data demonstrate that the activation of the EC
system in the brain is sufﬁcient to induce hepatic insulin
resistance.
FIG. 1. Intracerebroventricular CB1 activation impairs hepatic insulin action. A: Scheme depicting the clamp protocol. B: Blood glucose throughout
the experiments (n ‡ 6). C–E: Intracerebroventricular WIN infusion induces hepatic insulin resistance (n ‡ 8). C: Hepatic glucose production
(hGP) before and during the clamp. D: Percent suppression of hGP. E: Peripheral glucose utilization (Rd) during the clamp. F–H: Intra-
cerebroventricular ACEA infusion impairs hepatic insulin sensitivity (n ‡ 6). F: hGP before and during the clamp. G: Percent suppression of hGP.
H: Rd during the clamp. See also Supplementary Fig. 1 and Supplementary Table 1. Data are presented as means 6 SE. *P < 0.05, **P < 0.01.
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ACEA induces hepatic insulin resistance. Because
WIN can activate both CB1 and CB2 (39), we wanted to test
whether it is the activation of CB1 rather than CB2 or
a drug-speciﬁc effect of WIN that impairs hepatic insulin
action. Therefore, we infused the highly speciﬁcC B 1 ag-
onist ACEA intracerebroventricularly while performing
hyperinsulinemic, euglycemic clamp studies (Fig. 1A).
Blood glucose was controlled throughout the clamp, and
hyperinsulinemia was achieved in all rats (Fig. 1B and
Supplementary Fig. 1C). As with intracerebroventricular
WIN, intracerebroventricular ACEA infusion tended to el-
evate hGP at baseline and resulted in a signiﬁcantly higher
hGP during the hyperinsulinemic clamp (Fig. 1F). There-
fore, intracerebroventricular ACEA infusion signiﬁcantly
impaired the insulin-induced suppression of hGP (66% with
vehicle vs. 52% with ACEA) (Fig. 1G). It is noteworthy that
the Rd in the intracerebroventricular ACEA-infused group
tended to be higher, as seen with intracerebroventricular
WIN infusion (Fig. 1H), which could explain why the GIR
was not different despite the markedly blunted suppres-
sion of hGP (Supplementary Fig. 1D). These data conﬁrm
our above ﬁnding that central EC system activation in-
duces hepatic insulin resistance, further highlighting the
importance of brain CB1 in regulating hepatic insulin action.
Central CB1 activation impairs hepatic glucose ﬂuxes
without affecting hepatic insulin signaling. To de-
termine whether the impaired hepatic insulin action seen
with intracerebroventricular WIN and ACEA were because
of deﬁcits in hepatic insulin signaling, we performed
Western blot analyses of livers harvested at the end of the
hyperinsulinemic clamps (Fig. 2A and B). Phosphorylation
and expression of AKT and glycogen synthase kinase 3
(GSK3), major downstream targets of insulin signaling, were
unchanged with either WIN or ACEA infusions. These ﬁnd-
ings suggest that central CB1 activation impairs hGP in-
dependent of hepatic insulin signaling, consistent with our
observations that both central insulin and leptin (40) acutely
suppress hGP without altering hepatic insulin signaling.
Because AMP-activated protein kinase (AMPK) is be-
lieved to play an important role in regulating hGP (41), we
also assessed AMPK phosphorylation. We found that
ACEA infusion moderately decreased AMPK phosphory-
lation (Fig. 2B), and although we were not able to detect
this difference with intracerebroventricular WIN infusion,
it may in part contribute to the hepatic insulin resistance
induced by central EC system activation.
Central EC system activation impairs the ability of
systemic insulin to suppress WAT lipolysis. Increased
lipolytic ﬂux from WAT to the liver could provide a mech-
anism for the observed hepatic insulin resistance since
glycerol released from WAT can act as a substrate for
gluconeogenesis in the liver (42). Because we have dem-
onstrated recently that brain insulin regulates systemic li-
polysis (10) and studies have shown that lipolytic ﬂux can
regulate hGP (5,6), we investigated whether central EC
system activation might induce peripheral lipolysis, con-
sistent with impaired adipose tissue insulin action. To this
end, we assessed Ra of glycerol during hyperinsulinemic,
euglycemic clamp studies by infusing [
2H-5]glycerol. The
euglycemic clamp protocol used here enables us to study
the effects of central EC system activation on lipolytic ﬂux
while controlling circulating insulin and glucose, two ma-
jor regulators of lipolysis in adipocytes.
During baseline, intracerebroventricular WIN-infused
rats tended to have elevated Ra glycerol (Fig. 3A), although
this did not reach statistical signiﬁcance. However, during
the clamp, hyperinsulinemia suppressed lipolysis in vehicle-
infused rats, but not in intracerebroventricular WIN-infused
rats (Fig. 3A). Indeed, intracerebroventricular vehicle-
infused rats suppressed Ra glycerol by 47% during moderate
hyperinsulinemia, whereas intracerebroventricular WIN-
infused rats only suppressed Ra glycerol by 7% (Fig. 3B).
These data show that, in addition to the blunted sup-
pression of hGP with systemic hyperinsulinemia, intra-
cerebroventricular WIN infusion impairs the ability of
insulin to suppress lipolysis. The inability of the WIN-
infused animals to restrain lipolysis could contribute to
the impaired suppression of hGP, because it has been
shown that lipolytic ﬂux can regulate hGP (5,6). This is
highlighted by an inverse correlation between Ra glycerol
and hGP suppression (Fig. 3C), and although correlation
does not prove causation, it raises the possibility that the
impaired suppression of lipolysis is involved in the mecha-
nism regulating hGP.
To investigate the molecular mechanisms responsible
for the elevated lipolytic ﬂux in WIN-infused animals, we
performed Western blot analyses on WAT from clamped
rats. We assessed the activation states and protein ex-
pression of several key lipolytic enzymes, including com-
parative gene identiﬁcation-58 (CGI-58), HSL, ATGL, and
perilipin (43). Perilipin and CGI-58 are lipid droplet-
associated proteins. Upon phosphorylation, perilipin fa-
cilitates the access of lipolytic enzymes, such as ATGL
and HSL, to the lipid droplet and is believed to release
CGI-58, which in turn activates ATGL. ATGL hydrolyzes
triacylglycerols to diacylglycerols, which are then fur-
ther hydrolyzed to monoacylglycerols by HSL (44). We
found that intracerebroventricular WIN infusion increased
perilipin phosphorylation and CGI-58 expression (Fig. 3D),
suggesting that ATGL is activated. We also saw consistent
FIG. 2. Central CB1 activation impairs hepatic insulin action without
affecting hepatic insulin signaling. A and B: Western blot analyses of
livers from clamped rats infused with vehicle or WIN (A; n =8 )o ri n -
fused with vehicle or ACEA (B; n = 7). Membranes were probed with
antibodies against phospho-AKT, GSK3, GAPDH, or phospho-AMPK.
Representative blots are on the left, and quantiﬁcations are on the
right. Data were normalized to GAPDH expression and are expressed as
fold change compared with vehicle 6 SE. *P > 0.05.
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activating serine phosphorylation sites on HSL. Overall, this
increased activation of several key lipolytic enzymes could
contribute to the elevated lipolytic ﬂux seen with intra-
cerebroventricular WIN infusion.
Central CB1 blockade ameliorates overfeeding-induced
insulin resistance. We next wanted to understand the
role of brain CB1 in a pathophysiological state of insulin
resistance. We induced insulin resistance by exposing
SD rats to HFD for 3 days and allowing them to overeat
(Supplementary Fig. 2A). This model is characterized by
hepatic insulin resistance, whereas peripheral glucose
utilization is not yet reduced (45,46). Thus this is a model
of early insulin resistance lacking secondary confounding
factors, including impaired glucose utilization in muscle
and WAT and a chronic proinﬂammatory state, that are
associated with long-standing insulin resistance and di-
abetes. One of the key defects in this model is impaired
hypothalamic insulin action, which is a failure of MBH-
infused insulin to suppress hGP (13).
To test whether increased EC tone in the CNS is re-
sponsible for the impaired insulin action, we blocked
EC signaling in the brain by infusing rimonabant intra-
cerebroventricularly while elevating circulating insulin
levels and controlling glucose with a hyperinsulinemic,
euglycemic clamp (scheme in Fig. 4A, insulin and glucose
levels in Supplementary Fig. 2B and C). During baseline,
hGP was similar between groups, whereas during the
clamp the rats infused with rimonabant had signiﬁcantly
lower hGP than HFD vehicle rats (Fig. 4B). Thus although
HFD vehicle-treated rats suppressed hGP by only 53%, rats
infused with rimonabant suppressed hGP by 79% (Fig. 4C).
It is noteworthy that intracerebroventricular rimonabant
infusion tended to decrease the Rd (Fig. 4D) and, although
not statistically signiﬁcant, it complements the elevation in
Rd seen with CB1 activation by WIN and ACEA infusions.
Intracerebroventricular rimonabant mildly increased the
GIR (Supplementary Fig. 2D), although this did not reach
statistical signiﬁcance. These data demonstrate that cen-
tral CB1 blockade can restore hepatic insulin action, as-
cribing a critical role to increased EC tone in the brain in
the development of early insulin resistance.
DISCUSSION
Here we demonstrated that elevated EC tone in the brain is
sufﬁcient to induce hepatic insulin resistance. By use of
pancreatic clamp studies, we showed that central infu-
sions of the CB1 and CB2 agonist WIN and the speciﬁcC B 1
agonist ACEA impair the ability of systemic hyperin-
sulinemia to suppress hGP. Conversely, in a model of early
insulin resistance characterized by hepatic insulin re-
sistance, central CB1 blockade was sufﬁcient to restore
FIG. 3. Central CB1 activation blunts insulin-mediated suppression of lipolysis. A: Ra glycerol in plasma before and during hyperinsulinemic clamps
in intracerebroventricular vehicle and WIN-infused rats (n =4 ) .B: Percent suppression of Ra glycerol during the clamp (n =4 ) .C: Correlation
between hGP suppression and Ra glycerol (n =4 ,P < 0.05). D: Western blot analyses of lipolytic protein expression and phosphorylation in WAT
from clamped rats. Data are normalized to b-actin and expressed as fold change compared with vehicle (n = 8). Data are presented as means 6 SE.
*P < 0.05, **P < 0.01.
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velop hepatic and hypothalamic insulin resistance (13).
Because animal models of obesity are accompanied by el-
evated brain and hypothalamic EC levels (20,21), we hy-
pothesized that elevated central EC tone might impair
hypothalamic insulin action. By infusing rimonabant intra-
cerebroventricularly, we were able to restore hepatic insulin
action caused by overfeeding, emphasizing the relevance of
brain CB1 in the control of hepatic metabolism.
Our second major ﬁnding is that central CB1 activation
increases systemic lipolysis. We have recently shown that
both systemic lipolysis and hGP can be regulated through
brain insulin signaling (10), and because lipolytic ﬂux can
affect hGP (5,6), we investigated lipolysis after central EC
system activation. The elevation in lipolysis after intra-
cerebroventricular WIN administration increases the ﬂux
of glycerol from WAT to the liver, where glycerol would
serve as a gluconeogenic substrate, which then contributes
to the increased hGP observed during the clamp studies.
Therefore, our data support the notion that brain EC tone
impairs hypothalamic insulin action not only at the liver
but also in WAT.
We measured lipolysis with Ra glycerol through the
tracer dilution technique (36), which provides a good es-
timate of WAT lipolysis (42) for two reasons. First, WAT
has very low glycerokinase activity (approximately 1,000-
fold lower than liver [47]), and therefore WAT lipolysis
results in glycerol release. Second, the liver releases less
than 10% of all systemic glycerol (48). Thus, although WAT
glycerol release does not entirely account for the Ra
glycerol, WAT is the major contributor. We further com-
plement this estimate of whole body glycerol ﬂux by
measuring the activation states of HSL and perilipin as
estimates of local lipolytic activity. Both measurements
support our conclusion that the central EC system regu-
lates lipolysis in WAT.
It is interesting that both CB1 agonists tended to in-
crease peripheral glucose utilization, whereas the antago-
nist rimonabant tended to decrease this parameter during
the intracerebroventricular infusions. Although the effect
size was small and our data did not reach statistical sig-
niﬁcance, the trends were consistent in each of the three
studies, raising the possibility that central CB1 signaling
increases peripheral glucose utilization. We speculate that
this could be mediated through increased sympathetic
outﬂow to muscle as has been described recently (49),
because muscle is the major glucose utilizing organ, al-
though other tissues may be involved. Therefore, with
central CB1 activation, the elevated Rd could compensate for
the decreased hGP suppression, resulting in an unchanged
GIR. Likewise, in the rimonabant-infused rats, enhanced
hGP suppression could be tempered by this decreased Rd,
resulting in a moderate overall increase in GIR.
Whether our studies translate to human physiology is
unclear. Although the relevance of neuronal insulin sig-
naling in regulating hGP has been established in rodents
through pharmacological and genetic studies (4), the
physiological relevance of this regulatory pathway remains
uncertain in higher species. Cherrington’s group recently
found that brain insulin does regulate hGP in dogs (50),
although the effect magnitude was modest, possibly be-
cause of species discrepancies and differences in the ex-
perimental design of the clamp studies compared with
earlier rodent studies. In humans, insulin regulates neu-
ronal activity (51) and participates in weight regulation
(52). However, whether brain insulin participates in the
regulation of hGP and/or lipolysis remains unstudied in
humans. One of the reasons why brain insulin could be
more relevant in rodent physiology than in human is that
rodents may exhibit a higher basal neural tone to the liver
as has been previously suggested (53).
Our results with brain infusions of the CB1 antagonist
rimonabant differ from those obtained by Nogueiras et al.
(32), where prolonged intracerebroventricular rimonabant
treatment in a long-standing model of diet-induced obesity
did not improve hepatic insulin sensitivity. It is important
to point out some differences in the models used in these
studies. We studied an early model of high-fat feeding-
induced insulin resistance that is chieﬂy associated with
hepatic insulin resistance (45) and characterized by im-
paired hypothalamic insulin action (13). Thus this model
lacks the secondary sequela of long-term high-fat feeding,
such as impaired glucose utilization and chronic in-
ﬂammation. Conversely, Nogueiras et al. studied a model
of prolonged high-fat feeding (32) where these complica-
tions are likely present and where the peripherally in-
creased EC tone may become more prominent (18,54).
Furthermore, our rimonabant dose was different. Whereas
Nogueiras et al. (32) infused 5 mg per day, we infused 6.25
mg over a 6-h period. Our chosen intracerebroventricular
dose was approximately 1% of the widely used dose of
10 mg/kg ip, which was also used in the abovementioned
studies (32). It is possible that the intracerebroventricular
dose chosen by Nogueiras et al. (32) was not sufﬁcient to
reveal effects of isolated brain CB1 antagonism, or that in
a model of longer-standing insulin resistance isolated
central CB1 antagonism is not enough to reverse the met-
abolic phenotype.
The role of neuronal EC signaling in regulating energy
homeostasis has been highlighted in a study where CB1
receptors were knocked out in CAMKIIa expressing neu-
rons, including forebrain and sympathetic ganglions (34).
FIG. 4. Intracerebroventricular rimonabant restores hepatic insulin
sensitivity after short-term overfeeding. A: Experimental protocol. B:
hGP before and during the clamp. C: Percent suppression of hGP during
the clamp. D: Rd during the clamp. See also Supplementary Fig. 2 and
Supplementary Table 2. Data are presented as means 6 SE; n =5 .* * P <
0.01, ***P < 0.001.
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to diet-induced obesity and insulin resistance. Although
these mice were essentially unaffected by rimonabant
treatment, the study did not answer the question whether
the beneﬁcial effects of pharmacological CB1 antagonism
are mediated through central versus peripheral mecha-
nisms. Our study demonstrates that brain EC signaling
does play an important role in regulating lipolysis, hGP,
and possibly peripheral glucose utilization.
It has been shown that short-term overfeeding leads to
hypothalamic insulin resistance (13). We speculate that
this could be due, in large part, to the dysregulation of the
EC system. The activation of the EC system in the brain
blunts the ability of insulin to suppress both hGP and li-
polysis, similar to what we found by infusing an insulin
antagonist into the MBH (10). Under normal conditions,
insulin could generate a signal in the MBH that is mediated
through descending neuronal pathways that innervate
WAT (12,55), resulting in the suppression of lipolysis.
However, during states of elevated EC tone, ECs may act
as retrograde inhibitors of synaptic transmission and
thereby impair hypothalamic insulin action, potentially
even in the absence of impaired intracellular insulin sig-
naling. By infusing rimonabant intracerebroventricularly,
we released this blockade on insulin-induced synaptic
transmission and restored hepatic and WAT insulin action.
These data strongly suggest that central EC tone plays an
important role in the development of hypothalamic insulin
resistance. Although our study does not negate prior work
suggesting that the EC system has important peripheral
effects, we do demonstrate that the central EC system
acutely participates in the regulation of systemic glucose
and lipid homeostasis. Therefore, a peripherally restricted
CB1 antagonist might not be as therapeutically potent as
the brain-penetrating rimonabant, although it is likely that
the feared psychiatric side effects would be avoided.
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